Pharmacokinetic principles distribution

One of the factors that can alter the response to drugs is the concurrent administration of other drugs. There are several mechanisms by which drugs may interact, but most can be categorized as pharmacokinetic (absorption, distribution, metabolism, excretion), pharmacodynamic (additive or antagonistic effects), or combined interactions. The general principles of pharmacokinetics are discussed in Chapters 3 and 4 the general principles of pharmacodynamics in Chapter... 

Pharmacokinetic principles, which deal with the absorption, distribution, binding, biotrans-formation, and excretion of drugs and their metabolites in the body (Figure 1.1), are the topic of this chapter. 

As mentioned in Chapter 4, experiments have determined that the distribution of ASOs into tissues is nonlinear. This revelation invalidates the above BAV equation in that it is dependent on linear pharmacokinetics and the principle of superposition. A way to circumvent this problem is to decrease the drag input function (i.e., systemic presentation of the ASO) such that ASO plasma concentrations are maintained below the level at which saturation, and thus nonlinearity of the distribution processes, occurs. Drug administration by SC rather than IV administration has a reduced drug input rate and can produce such a scenario. The corresponding plasma-derived data are then suitable for the determination of absolute bioavailability - consistent with linear pharmacokinetic principles and the following equation ... 

Furthermore, pharmacokinetic administration, distribution, metabolism and excretion (ADME) factors affect drug bioavailability, efficacy and safety, and, thus, are a vital consideration in the selection process of oral drug candidates in development pipelines. Since solubility, permeability, and the fraction of dose absorbed are fundamental BCS parameters that affect ADME, these BCS parameters should prove useful in drug discovery and development. In particular, the classification can used to make the development process more efficient.For example, in the case of a drug placed in BCS Class II where dissolution is the rate-limiting step to absorption, formulation principles such as polymorph selection, salt selection, complex formation, and particle size reduction (i.e., nanoparticles) could be applied earlier in development to improve bioavailability. 

It is a general pharmacokinetic principle, which is also applicable to peptides and proteins, that only the free, unbound fraction of a drug substance is accessible to distribution and elimination processes as well as interactions with its target structure (e.g. receptor) at the site of action. Hence, the activity of a drug is better characterized by its free rather than total concentration if there is no constant relationship between free and total drug concentration. 

The present volume of the series Methods and Principles in Medicinal Chemistry focuses on the impact of pharmacokinetics and metabolism in Drug Design. Pharmacokinetics is the study of the kinetics of absorption, distribution, metabolism, and excretion of drugs and their pharmacologic, therapeutic, or toxic response in animals and man. 

The basic principles outlined above can be applied to the interpretation of clinical drug concentration measurements on the basis of three major pharmacokinetic variables absorption, clearance, and volume of distribution (and the derived variable, half-life) and two pharmacodynamic variables maximum effect attainable in the target tissue and the sensitivity of the tissue to the drug. Diseases may modify all of these parameters, and the ability to predict the effect of disease states on pharmacokinetic parameters is important in properly adjusting dosage in such cases. (See The Target Concentration Strategy.)... 

The explanation of the pharmacokinetics or toxicokinetics involved in absorption, distribution, and elimination processes is a highly specialized branch of toxicology, and is beyond the scope of this chapter. However, here we introduce a few basic concepts that are related to the several transport rate processes that we described earlier in this chapter. Toxicokinetics is an extension of pharmacokinetics in that these studies are conducted at higher doses than pharmacokinetic studies and the principles of pharmacokinetics are applied to xenobiotics. In addition these studies are essential to provide information on the fate of the xenobiotic following exposure by a define route. This information is essential if one is to adequately interpret the dose-response relationship in the risk assessment process. In recent years these toxicokinetic data from laboratory animals have started to be utilized in physiologically based pharmacokinetic (PBPK) models to help extrapolations to low-dose exposures in humans. The ultimate aim in all of these analyses is to provide an estimate of tissue concentrations at the target site associated with the toxicity. 

The optimal administration of drugs in clinical practice is facilitated by effective application of the principles of clinical pharmacokinetics (PK) and pharmacodynamics (PD). Relationships between drug levels in the systemic circulation and various body compartments (e.g., tissues and biophase) following drug administration depend on factors governing drug absorption, distribution, elimination, and excretion (ADME). Collectively, the study of the factors that govern the ADME processes is termed pharmacokinetics. 

The nonlinear mixed-effects method is depicted in Figure 10.4 and is described here using the conventions of the NONMEM software (2, 3) and the description by Vozeh ef a/. (3). It is based on the principle that the individual pharmacokinetic parameters of a patient population arise from a distribution that can be described by the population mean and the interindividual variance. Each individual pharmacokinetic parameter can be expressed as a population mean and a deviation, typical for an individual. The deviation is the difference between the population mean and the individual parameter and is assumed to be... 

The distribution and disposition of a drug in the body result from a complex set of physiological processes and biochemical interactions. In principle, it is possible to describe these processes and interactions in mathematical terms and, if sufficient data are available, to predict the time course of drug and metabolite(s) in different species and at specific anatomic sites (15). A physiological pharmacokinetic model was developed to predict the deamination of cytosine arabinoside (ARA-C) in humans from enzyme parameters determined from homogenates of human tissue (16). ARA-C is converted to its inactive metabolite, uracil arabinoside (ARA-U) by cytidine deaminase, the activity of which varies substantially among tissues. 

The fundamental principle of toxicology is the concept that the sixteenth century physician Paracelsus articulated in the 1500s sola dosis facit venenum or the dose makes the poison . The modem version of this observation is the dose-response relationship, which is experimentally and theoretically supported through pharmacokinetic and pharmacodynamic experimentation. Pharmacokinetics is concerned with the study of the time course of the disposition of drugs, specifically absorption, distribution, metabolism and elimination, often referred to as ADME. In non-technical terms it can be thought of as what the body does to the chemical. An understanding of the pharmacokinetic (in the case of dmgs) or toxicokinetic (all chemicals) profile is critical to estimate the... 

Chapter 1 discussed the principles of drug pharmacokinetics here the importance of volumes of distribution (Pj), drug ionization and protein binding are outlined for antimicrobial drugs. 

The standardized guidelines have been compiled to cover test methods in animal studies and in vitro studies on absorption, distribution, metabolism cind excretion in the Notification No. 496 of the PAB in 1998. The guidelines can be applicable for the drugs to be submitted after October 1999. The following principles should be considered in order to select the most appropriate methods bcised on the characteristics of test substance. It is required that the exposure data related to toxicological studies be obtained before the first human study and other pharmacokinetic data before the completion of Phcise I study in principle in accordance with the guidelines on nonclinical safety studies for conducting clinical trials (Notification No. 1019 of the PAB, 1998). 

Pharmacokinetics describes the processes of the uptake of drugs by the body, the biotransformations they undergo, the distribution of the drugs and their metabolites in tissue, and the elimination of the drugs and their metabolites from the body. Clinical pharmacokinetics is the discipline that applies the principles of pharmacokinetics to safe and effective therapeutic management of an individual patient. It is this aspect of pharmacology that most strongly influences the interpretation of TDM results and that is dealt with in more detail in this chapter. 

---